{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:03:27Z","timestamp":1790949807637,"version":"4.1.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"NIH-NIAMS","award":["R01AR073191"],"award-info":[{"award-number":["R01AR073191"]}]},{"name":"NIH-NIAMS","award":["P30 AR075042"],"award-info":[{"award-number":["P30 AR075042"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Combined treatment with PTH receptor stimulation (teriparatide 20-\u03bcg) and RANKL inhibition (denosumab 60-mg) increases spine and hip BMD and improves estimates of bone strength to a greater extent than either monotherapy. The mechanisms underlying the enhanced efficacy of this combination, however, are not fully defined. In this randomized, 3-arm interventional trial, postmenopausal women with osteoporosis were randomized to receive denosumab 60-mg (n\u2009=\u20099), teriparatide 20-\u03bcg (n\u2009=\u200913), or both (n\u2009=\u200912) for 3\u00a0mo. Participants received double fluorochrome labeling and underwent a single iliac crest bone biopsy at month 3. A total of 26 bone biopsies were suitable for histomorphometry. Fluorescence microscopy was utilized to differentiate remodeling-based from modeling-based bone formation in the cancellous and endocortical envelopes by identifying the morphology of underlying cement lines as either scalloped or smooth, respectively. Within-subject 3-mo changes from baseline were compared among the 3 treatment groups using one-way ANOVA. At 3\u00a0mo, teriparatide significantly increased histomorphometric indices of bone formation (BFR\/BS, MS\/BS, and dLS\/BS) compared to denosumab or combination therapy, consistent with its greater effect on bone formation markers. Although both remodeling- and modeling-based bone formation increased in the combination group, denosumab attenuated the teriparatide-induced increases bone in formation, except for modeling-based bone formation in the endocortical envelope. These findings suggest that the greater increases in BMD observed with combined denosumab and teriparatide in the Denosumab and Teriparatide Administration study may result from the net effect of denosumab-mediated remodeling suppression which leads to a reduction in cortical porosity and enables secondary mineralization of the preserved bone volume and teriparatide-induced bone formation.<\/jats:p>","DOI":"10.1093\/jbmr\/zjaf152","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T11:52:56Z","timestamp":1761133976000},"page":"497-506","source":"Crossref","is-referenced-by-count":5,"title":["Comparative bone histomorphometry effects of combined denosumab and teriparatide vs monotherapy in postmenopausal women with osteoporosis: a randomized controlled trial"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6755-8469","authenticated-orcid":false,"given":"Sabashini K","family":"Ramchand","sequence":"first","affiliation":[{"name":"Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard Medical School , Boston, MA 02114 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy N","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard Medical School , Boston, MA 02114 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingshe","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Massachusetts General Hospital, Harvard Medical School , Boston, MA 02114 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart H","family":"Hershman","sequence":"additional","affiliation":[{"name":"Biostatistics Center, Massachusetts General Hospital, Harvard Medical School , Boston, MA 02114 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G","family":"Tobert","sequence":"additional","affiliation":[{"name":"Biostatistics Center, Massachusetts General Hospital, Harvard Medical School , Boston, MA 02114 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3498-236X","authenticated-orcid":false,"given":"Hang","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Medicine, Endocrine Unit, Massachusetts General Hospital , Boston, MA 02114 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janaina S","family":"Martins","sequence":"additional","affiliation":[{"name":"Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard Medical School , Boston, MA 02114 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie L","family":"David","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Massachusetts General Hospital, Harvard Medical School , Boston, MA 02114 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Sassana-Khadka","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Massachusetts General Hospital, Harvard Medical School , Boston, MA 02114 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savannah","family":"Ryan","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Massachusetts General Hospital, Harvard Medical School , Boston, MA 02114 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie B","family":"Demay","sequence":"additional","affiliation":[{"name":"Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard Medical School , Boston, MA 02114 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2051-0505","authenticated-orcid":false,"given":"Benjamin Z","family":"Leder","sequence":"additional","affiliation":[{"name":"Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard Medical School , Boston, MA 02114 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"issue":"9886","key":"2026081703272367400_ref1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"issue":"5","key":"2026081703272367400_ref2","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1210\/jc.2013-4440","article-title":"Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (the DATA extension study): a randomized controlled trial","volume":"99","author":"Leder","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026081703272367400_ref3","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1210\/jc.2016-1160","article-title":"Effects of two years of teriparatide, denosumab, or both on bone microarchitecture and strength (DATA-HRpQCT study)","volume":"101","author":"Tsai","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026081703272367400_ref4","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/S8756-3282(03)00202-3","article-title":"Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure","volume":"33","author":"Frolik","year":"2003","journal-title":"Bone"},{"issue":"5","key":"2026081703272367400_ref5","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1210\/er.2004-0006","article-title":"Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use","volume":"26","author":"Hodsman","year":"2005","journal-title":"Endocr Rev"},{"issue":"19","key":"2026081703272367400_ref6","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"issue":"4","key":"2026081703272367400_ref7","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1210\/jc.2015-3698","article-title":"Effect of teriparatide on bone formation in the human femoral neck","volume":"101","author":"Cosman","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026081703272367400_ref8","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1002\/jbmr.1784","article-title":"Differing effects of PTH 1-34, PTH 1-84, and zoledronic acid on bone microarchitecture and estimated strength in postmenopausal women with osteoporosis: an 18-month open-labeled observational study using HR-pQCT","volume":"28","author":"Hansen","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026081703272367400_ref9","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00198-010-1226-1","article-title":"Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis","volume":"22","author":"Macdonald","year":"2011","journal-title":"Osteoporos Int"},{"issue":"2","key":"2026081703272367400_ref10","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/jbmr.3309","article-title":"Remodeling- and modeling-based bone formation with teriparatide versus denosumab: a longitudinal analysis from baseline to 3 months in the AVA study","volume":"33","author":"Dempster","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2026081703272367400_ref11","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1210\/jc.2007-2814","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women","volume":"93","author":"Bone","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026081703272367400_ref12","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/jbmr.251","article-title":"Effects of denosumab on bone turnover markers in postmenopausal osteoporosis","volume":"26","author":"Eastell","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2026081703272367400_ref13","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"2026081703272367400_ref14","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"7","key":"2026081703272367400_ref15","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1210\/jc.2017-02669","article-title":"Effects of long-term denosumab on bone histomorphometry and mineralization in women with postmenopausal osteoporosis","volume":"103","author":"Dempster","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026081703272367400_ref16","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/jbmr.448","article-title":"Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study","volume":"26","author":"Brown","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2026081703272367400_ref17","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1002\/jbmr.2236","article-title":"Effects of up to 5 years of denosumab treatment on bone histology and histomorphometry: the FREEDOM study extension","volume":"29","author":"Brown","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2026081703272367400_ref18","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1210\/jc.2009-1703","article-title":"Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis","volume":"95","author":"Finkelstein","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"13","key":"2026081703272367400_ref19","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med"},{"key":"2026081703272367400_ref20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/bonekey.2012.47","article-title":"Histomorphometric interpretation of bone biopsies for the evaluation of osteoporosis treatment","volume":"1","author":"Compston","year":"2012","journal-title":"Bonekey Rep"},{"issue":"3","key":"2026081703272367400_ref21","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1359\/JBMR.051109","article-title":"A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide","volume":"21","author":"Lindsay","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026081703272367400_ref22","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/jbmr.1818","article-title":"Double and quadruple tetracycline labeling of bone: impact of the label itself","volume":"28","author":"Lindsay","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2026081703272367400_ref23","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqae142","article-title":"Evaluation of osteogenic phenotype in postmenopausal women receiving anabolic and antiresorptive osteoporosis therapies","volume":"165","author":"Kobelski","year":"2024","journal-title":"Endocrinology"},{"issue":"10","key":"2026081703272367400_ref24","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/jbmr.5650051010","article-title":"Frequency distributions of tetracycline-based measurements: implications for the interpretation of bone formation indices in the absence of double-labeled surfaces","volume":"5","author":"Foldes","year":"1990","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026081703272367400_ref25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/jbmr.1805","article-title":"Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee","volume":"28","author":"Dempster","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026081703272367400_ref26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/jbmr.2315","article-title":"Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength: the DATA-HRpQCT study","volume":"30","author":"Tsai","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2026081703272367400_ref27","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1210\/jc.2015-4181","article-title":"Differential effects of teriparatide and denosumab on intact PTH and bone formation indices: AVA osteoporosis study","volume":"101","author":"Dempster","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026081703272367400_ref28","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjaf152\/64882676\/zjaf152.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/41\/5\/497\/64882676\/zjaf152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/41\/5\/497\/64882676\/zjaf152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T07:27:30Z","timestamp":1786951650000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/41\/5\/497\/8300253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,10,23]]},"published-print":{"date-parts":[[2026,4,26]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmr\/zjaf152","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2025,10,23]]}}}